• Circassia Ltd., of Oxford, UK, started a pivotal, large-scale Phase III study of its ToleroMune cat allergy treatment for rhinoconjunctivitis. The study will test safety and efficacy of the ToleroMune treatment in approximately 1,200 subjects from the U.S., Canada and Europe.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter